Novavax, Inc. (NVAX) Earns Hold Rating from Piper Jaffray Companies
Piper Jaffray Companies reiterated their hold rating on shares of Novavax, Inc. (NASDAQ:NVAX) in a research note issued to investors on Wednesday. The firm currently has a $1.50 price target on the biopharmaceutical company’s stock.
Several other equities analysts also recently weighed in on NVAX. Cantor Fitzgerald set a $2.00 price target on Novavax and gave the stock a hold rating in a research report on Monday, May 8th. ValuEngine downgraded Novavax from a sell rating to a strong sell rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded Novavax from a buy rating to a hold rating in a research report on Friday, June 9th. Finally, BidaskClub downgraded Novavax from a hold rating to a sell rating in a research report on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $5.61.
Shares of Novavax (NASDAQ:NVAX) opened at 0.9596 on Wednesday. Novavax has a one year low of $0.73 and a one year high of $8.49. The firm has a 50-day moving average price of $1.17 and a 200 day moving average price of $1.18. The stock’s market capitalization is $271.18 million.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The company had revenue of $5.68 million during the quarter, compared to the consensus estimate of $6.17 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,466.36%. Novavax’s revenue was up 34.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.29) earnings per share. On average, equities analysts expect that Novavax will post ($0.61) EPS for the current fiscal year.
In other Novavax news, insider Stanley C. Erck acquired 50,000 shares of the stock in a transaction dated Thursday, May 11th. The stock was acquired at an average price of $0.84 per share, with a total value of $42,000.00. Following the completion of the transaction, the insider now directly owns 128,279 shares in the company, valued at $107,754.36. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders bought 105,000 shares of company stock valued at $90,800. Company insiders own 4.00% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Creative Planning increased its stake in shares of Novavax by 45.7% in the second quarter. Creative Planning now owns 472,198 shares of the biopharmaceutical company’s stock worth $543,000 after buying an additional 148,139 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Novavax by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 728,790 shares of the biopharmaceutical company’s stock worth $933,000 after buying an additional 201,795 shares in the last quarter. HighTower Advisors LLC increased its stake in shares of Novavax by 3.8% in the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 5,250 shares in the last quarter. Credit Suisse AG increased its stake in shares of Novavax by 37.1% in the first quarter. Credit Suisse AG now owns 1,519,495 shares of the biopharmaceutical company’s stock worth $1,945,000 after buying an additional 411,371 shares in the last quarter. Finally, KCG Holdings Inc. increased its stake in shares of Novavax by 161.0% in the first quarter. KCG Holdings Inc. now owns 178,797 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 110,292 shares in the last quarter. 50.04% of the stock is owned by institutional investors and hedge funds.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.